Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

NCT00569582 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT00569582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00569582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
Not reported
Enrollment
50 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's syndrome